Can serum apolipoprotein C-I demonstrate metabolic abnormality early in women with polycystic ovary syndrome?
To evaluate the role of apolipoprotein C-I (apoC-I) levels and assess relationships between apoC-I and clinical features in women with polycystic ovary syndrome (PCOS). Prospective study. Reproductive Center of Peking University Third Hospital. Thirty patients with PCOS with insulin resistance, 30 patients with PCOS without insulin resistance, and 30 control individuals. Fasting serum samples. Measures of serum apoC-I, androgens, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apoA1, apoB, heat-shock C-reactive protein, glucose, and homeostasis model assessment of insulin resistance (HOMA-IR). We found differentially expressed proteins by use of the surface-enhanced laser adsorption/ionization (SELDI) protein chip in the serum of women with PCOS and controls. Of these, apoC-I, was highly up-regulated. ApoC-I is associated with glycometabolism and lipid metabolism, but its role in PCOS has been unknown. The serum levels of apoC-I in the patients with PCOS were statistically significantly elevated compared with those of controls, especially in women with insulin resistance. The lean PCOS women had higher apoC-I levels than controls. In patients with PCOS and without any abnormal serum lipid index, apoC-I levels were still higher than in controls. Analysis showed that apoC-I correlated with body mass index, triglycerides, high-density lipoprotein cholesterol, apoA1, and HOMA-IR. ApoC-I may have an important role in glucose and lipid metabolism, and may be useful for early demonstration of metabolic abnormality in women with PCOS.